Have questions? Visit https://www.reddit.com/r/SNPedia

rs614367

From SNPedia

Orientationplus
Stabilizedplus
Make rs614367(C;C)
Make rs614367(C;T)
Make rs614367(T;T)
ReferenceGRCh38 38.1/141
Chromosome11
Position69513996
is asnp
is mentioned by
dbSNPrs614367
dbSNP (classic)rs614367
ClinGenrs614367
ebirs614367
HLIrs614367
Exacrs614367
Gnomadrs614367
Varsomers614367
LitVarrs614367
Maprs614367
PheGenIrs614367
Biobankrs614367
1000 genomesrs614367
hgdprs614367
ensemblrs614367
geneviewrs614367
scholarrs614367
googlers614367
pharmgkbrs614367
gwascentralrs614367
openSNPrs614367
23andMers614367
SNPshotrs614367
SNPdbers614367
MSV3drs614367
GWAS Ctlgrs614367
GMAF0.09963
Max Magnitude0
? (C;C) (C;T) (T;T) 28


GWAS snp
PMID [PMID 20453838OA-icon.png]
Trait Breast cancer
Title Genome-wide association study identifies five new breast cancer susceptibility loci
Risk Allele T
P-val 3E-15
Odds Ratio 1.15 [1.10-1.20]


[PMID 21445572] Genetic polymorphisms and breast cancer risk: evidence from meta-analyses, pooled analyses, and genome-wide association studies


[PMID 22348646OA-icon.png] Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers


[PMID 22461340OA-icon.png] 11q13 is a susceptibility locus for hormone receptor positive breast cancer

GWAS snp
PMID [PMID 23535729OA-icon.png]
Trait Breast cancer
Title Large-scale genotyping identifies 41 new loci associated with breast cancer risk.
Risk Allele T
P-val 2E-63
Odds Ratio 1.21 [1.18-1.24]
GWAS snp
PMID [PMID 24493630OA-icon.png]
Trait Breast cancer (early onset)
Title A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age.
Risk Allele
P-val 1E-8
Odds Ratio 1.34 [NR]


[PMID 26248686] Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy


[PMID 30247654OA-icon.png] HACER: an atlas of human active enhancers to interpret regulatory variants.